Mirati Therapeutics, Inc.
MTA-Cooperative PRMT5 Inhibitors

Last updated:

Abstract:

The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

Status:
Application
Type:

Utility

Filling date:

11 Sep 2020

Issue date:

18 Mar 2021